866763-17-9Relevant articles and documents
CYCLIC INHIBITORS OF HEPATITIS B VIRUS
-
Page/Page column 76; 77, (2020/02/14)
The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing said compounds.
Optimization of ADME Properties for Sulfonamides Leading to the Discovery of a T-Type Calcium Channel Blocker, ABT-639
Zhang, Qingwei,Xia, Zhiren,Joshi, Shailen,Scott, Victoria E.,Jarvis, Michael F.
supporting information, p. 641 - 644 (2015/06/30)
The discovery of a novel peripherally acting and selective Cav3.2 T-type calcium channel blocker, ABT-639, is described. HTS hits 1 and 2, which have poor metabolic stability, were optimized to obtain 4, which has improved stability and oral bi
Site-specific covalent labeling of His-tag fused proteins with a reactive Ni(ii)-NTA probe
Uchinomiya, Sho-Hei,Nonaka, Hiroshi,Fujishima, Sho-Hei,Tsukiji, Shinya,Ojida, Akio,Hamachi, Itaru
supporting information; experimental part, p. 5880 - 5882 (2010/01/31)
A new method for covalent labeling of a His-tag fused protein with a small reactive probe was developed; this method is based on the complementary interaction between the His-tag and Ni(ii)-NTA, which facilitates a nucleophilic reaction between a histidin